ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - bictegravir as sodium; emtricitabine; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; bictegravir as sodium 50 mg - emtricitabine, tenofovir alafenamide and bictegravir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - bictegravir as sodium; emtricitabine; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; bictegravir as sodium 50 mg - emtricitabine, tenofovir alafenamide and bictegravir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - טבליות מצופות פילם - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme